IP Library Granted Patent US 10,980,835
Granted Patent B2
US 10,980,835 · App. 15/829,467 · Granted Apr 20, 2021

Arsenic trioxide for treatment of PIN1-associated disorders

Inventors: Kun Ping Lu (Newton, MA); Xiao Zhen Zhou (Newton, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc.
A61K33/36A61K9/0002A61K31/203A61P19/02A61P29/00A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,835
App. No.
15/829,467
Granted
Apr 20, 2021
Kind
B2
Abstract

The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.

Claims (10)

1. A method of inhibiting, reducing, or reversing the effect of increased Pin1 activity in one or more cells within a subject characterized as having a Pin1-associated disorder, said disorder resulting from increased Pin1 activity, said method comprising:

administering, as treatment for said increased Pin1 activity in said one or more cells within said subject, arsenic trioxide alone, or arsenic trioxide and a retinoic acid compound;

wherein said administration to said subject is sufficient to inhibit, reduce, or reverse the effect of increased Pin1 activity in said one or more cells within said subject,

wherein said increased Pin1 activity is due to a somatic mutation of Pin1, wherein said somatic mutation comprises one or more of the following:

a) Q33K;

b) E100D;

c) R36P;

d) G39C;

e) T143M; or

f) E145K.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 5, 2018
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045013/0317 →
Continuity (2)
Provisional Application 62429588 · Dec 2, 2016
Related Publication 20180153934A1 · Jun 7, 2018